The estimated Net Worth of Eric R Olson is at least $1.66 Million dollars as of 17 July 2023. Mr. Olson owns over 689 units of Syros Pharmaceuticals stock worth over $10,724 and over the last 8 years he sold SYRS stock worth over $47,750. In addition, he makes $1,605,420 as Chief Scientific Officer at Syros Pharmaceuticals.
Sign up
Mr. Olson SYRS stock SEC Form 4 insiders trading
Eric has made over 10 trades of the Syros Pharmaceuticals stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 689 units of SYRS stock worth $2,412 on 17 July 2023.
The largest trade he's ever made was exercising 15,750 units of Syros Pharmaceuticals stock on 17 August 2020 worth over $15,908. On average, Eric trades about 2,297 units every 115 days since 2017. As of 17 July 2023 he still owns at least 6,661 units of Syros Pharmaceuticals stock.
You can see the complete history of Mr. Olson stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Eric Olson biography
Eric R. Olson Ph.D. serves as Chief Scientific Officer of the Company. He previously served as research vice president for respiratory diseases at Vertex Pharmaceuticals, Inc., a biotechnology company, from 2001 to May 2013. Dr. Olson has also held positions as the director of antibacterials and molecular sciences departments at Warner-Lambert Co. as well as a research scientist focused on gene expression systems with The Upjohn Company, both of which were acquired by Pfizer Inc., a pharmaceutical company. Dr. Olson received a B.S. in microbiology and immunology from the University of Minnesota and a Ph.D. in microbiology and immunology from the University of Michigan.
What is the salary of Eric Olson?
As the Chief Scientific Officer of Syros Pharmaceuticals, the total compensation of Eric Olson at Syros Pharmaceuticals is $1,605,420. There are 4 executives at Syros Pharmaceuticals getting paid more, with Nancy Simonian having the highest compensation of $3,614,020.
How old is Eric Olson?
Eric Olson is 62, he's been the Chief Scientific Officer of Syros Pharmaceuticals since 2013. There are 6 older and 12 younger executives at Syros Pharmaceuticals. The oldest executive at Syros Pharmaceuticals Inc. is Phillip Sharp, 75, who is the Independent Director.
What's Eric Olson's mailing address?
Eric's mailing address filed with the SEC is C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE, MA, 02140.
Insiders trading at Syros Pharmaceuticals
Over the last 8 years, insiders at Syros Pharmaceuticals have traded over $8,259,551 worth of Syros Pharmaceuticals stock and bought 5,052,185 units worth $51,830,966 . The most active insiders traders include Group, Llc Green Jeremy Red..., Srinivas Akkaraju, and Stephane Bancel. On average, Syros Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $135,148. The most recent stock trade was executed by Richard A Young on 28 June 2024, trading 34,837 units of SYRS stock currently worth $178,365.
What does Syros Pharmaceuticals do?
syros pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical r&d. central to the syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of syros' senior leadership. while this scientific approach has applications in many therapeutic areas, syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.
What does Syros Pharmaceuticals's logo look like?
Complete history of Mr. Olson stock trades at Syros Pharmaceuticals
Syros Pharmaceuticals executives and stock owners
Syros Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Nancy Simonian,
President, Chief Executive Officer, Director -
Joseph Ferra,
Chief Financial Officer -
Jeremy Springhorn,
Chief Business Officer -
David Roth,
Chief Medical Officer -
Eric Olson,
Chief Scientific Officer -
Gerald Quirk,
Chief Legal & Administrative Officer -
Dr. Nancy A. Simonian M.D.,
Pres, CEO & Director -
Dr. David A. Roth,
Chief Medical Officer -
Dr. Eric R. Olson,
Chief Scientific Officer -
Richard Young,
Director -
Dr. Richard A. Young Ph.D.,
Scientific Founder, Member of Scientific Advisory Board & Director -
Mark Alles,
Independent Director -
Peter Wirth,
Independent Chairman of the Board -
Marsha Fanucci,
Independent Director -
Amir Nashat,
Independent Director -
Phillip Sharp,
Independent Director -
Srinivas Akkaraju,
Independent Director -
Hannah Deresiewicz,
IR Contact Officer -
S. Gail Eckhardt,
Director -
Dr. Christian C. Fritz Ph.D.,
Head of Biology -
Naomi Aoki,
VP of Corp. Communications & Investor Relations -
Gerald E. Quirk,
Chief Operations Officer & Sec. -
Jason Haas,
Chief Financial Officer -
Dr. Nathanael S. Gray Ph.D.,
Scientific Founder & Member of Scientific Advisory Board -
Dr. James E. Bradner M.D.,
Founder -
Alice Tsang Shaw,
Director -
Ventures Fund Iv, L.P.Flags...,
-
Sanj K Patel,
Director -
Vicki L Sato,
Director -
Michael W Bonney,
Director -
Colleen Elizabeth De Simone,
Principal Accounting Officer -
Robert Nelsen,
Director -
Venture Fund Vii, L.P.Arch ...,
-
Kyle D. Kuvalanka,
Chief Operating Officer -
Stephane Bancel,
Director -
Management Co. Vii, L.L.C.P...,
-
Pharm Tech Healthcare Fund ...,
10% owner -
Group, Llc Green Jeremy Red...,
-
Venture Fund Vii Lparch Ven...,
-
Healthcare Ventures Ii, L.P...,
10% owner -
James E Deerfield Mgmt L.P....,
-
Kristin Stephens,
Chief Development Officer -
Deborah Dunsire,
-
Jason Haas,
Chief Financial Officer -
Timothy Tyson,
-
Conley Chee,
President & CEO -
Andrew M. Oh,